Which analyst expects Cellectis S.A. (CLLS) to perform well in the near future?

As of close of business last night, Cellectis S.A.’s stock clocked out at $2.50, up 15.21% from its previous closing price of $2.17. In other words, the price has increased by $+0.3300 from its previous closing price. On the day, 155015 shares were traded. CLLS stock price reached its highest trading level at $2.5100 during the session, while it also had its lowest trading level at $2.2800.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



To gain a deeper understanding of CLLS’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.63 whereas as Long-Term Debt/Eq ratio is at 0.57.

Upgrades & Downgrades

On January 06, 2022, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $39 to $16.

On November 30, 2021, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $20.JMP Securities initiated its Mkt Outperform rating on November 30, 2021, with a $20 target price.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 5.07 while its Price-to-Book (P/B) ratio in mrq is 0.83.

Stock Price History:

Over the past 52 weeks, CLLS has reached a high of $9.57, while it has fallen to a 52-week low of $2.00. The 50-Day Moving Average of the stock is 2.4523, while the 200-Day Moving Average is calculated to be 3.3380.

Shares Statistics:

It appears that CLLS traded 81.13K shares on average per day over the past three months and 95.25k shares per day over the past ten days. A total of 45.54M shares are outstanding, with a floating share count of 45.37M. Shares short for CLLS as of Oct 13, 2022 were 674.42k with a Short Ratio of 0.58M, compared to 819.37k on Sep 14, 2022.

Earnings Estimates

As of right now, 8 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.45 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.88, while EPS last year was -$0.82. The consensus estimate for the next quarter is -$0.66, with high estimates of -$0.05 and low estimates of -$1.11.

Analysts are recommending an EPS of between -$1.19 and -$2.74 for the fiscal current year, implying an average EPS of -$2.22. EPS for the following year is -$2.13, with 9 analysts recommending between -$0.62 and -$3.28.

Revenue Estimates

In the current quarter, 7 analysts expect revenue to total $13.43M. It ranges from a high estimate of $42.2M to a low estimate of $2.23M. As of the current estimate, Cellectis S.A.’s year-ago sales were $10.83M, an estimated increase of 24.00% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $12.62M, a decrease of -7.60% less than the figure of $24.00% in the same quarter last year. There is a high estimate of $23.17M for the next quarter, whereas the lowest estimate is $3.33M.

A total of 8 analysts have provided revenue estimates for CLLS’s current fiscal year. The highest revenue estimate was $62M, while the lowest revenue estimate was $12M, resulting in an average revenue estimate of $31.69M. In the same quarter a year ago, actual revenue was $67.07M, down -52.80% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $53.92M in the next fiscal year. The high estimate is $138.97M and the low estimate is $13M. The average revenue growth estimate for next year is up 70.10% from the average revenue estimate for this year.